Longevity & AgingBPGbio's Mitochondrial Therapy Shows Promise in Children With Rare CoQ10 Disorder
BPGbio is advancing BPM31510, an investigational therapy for primary CoQ10 deficiency, a rare mitochondrial disease that causes progressive neurological decline, muscle weakness, and kidney failure in children. Unlike standard oral CoQ10 supplements, which fail to reliably reach the brain and kidneys, BPM31510 is designed to solve the delivery problem directly. Four children treated through compassionate use showed improvements in walking, balance, coordination, muscle strength, and fatigue within weeks. Animal studies confirmed the therapy increased CoQ10 levels in the brain and kidneys. Following a Type C meeting with the FDA, BPGbio is now preparing a pivotal Phase 3 trial, a significant regulatory milestone given the extremely small patient dataset.
